“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.
In this interview, Rafael Sanchez-Salas, MD, also discusses potential complications of focal therapy. Sanchez-Salas is an associate professor of urology in the department of surgery at McGill University in Montreal, Quebec.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.